The New York Times @nytimes
Breaking News: In a second vote, an FDA panel recommended authorizing a Pfizer booster for those 65 or older or at high risk of Covid. Earlier, the panel voted against recommending that they be authorized for everyone 16 or older. https://t.co/9bbreFu2KH — PolitiTweet.org